Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retigabine/Ezogabine Long-term Safety Extension in Pediatric Epilepsy
NCT01668654Phase 3Terminated
- Sponsor
- GSK
- Start
- Sep 2012
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of retigabine in epilepsy and Lennox-Gastaut syndrome (LGS), sponsored by GSK. Primary endpoints: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) up to 178 days, Number of Participants With AEs Leading to Withdrawal up to 178 days and 9 more. Started Sep 2012; status: terminated.
02
Drugs
retigabine
03
Conditions
epilepsyLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT01668654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01668654.